Logo image of CTX.CA

CRESCITA THERAPEUTICS INC (CTX.CA) Stock Fundamental Analysis

Canada - TSX:CTX - CA2258471028 - Common Stock

0.46 CAD
-0.01 (-2.13%)
Last: 10/21/2025, 7:00:00 PM
Fundamental Rating

2

Taking everything into account, CTX scores 2 out of 10 in our fundamental rating. CTX was compared to 33 industry peers in the Pharmaceuticals industry. The financial health of CTX is average, but there are quite some concerns on its profitability. CTX has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

CTX had negative earnings in the past year.
In the past year CTX had a positive cash flow from operations.
In multiple years CTX reported negative net income over the last 5 years.
The reported operating cash flow has been mixed in the past 5 years: CTX reported negative operating cash flow in multiple years.
CTX.CA Yearly Net Income VS EBIT VS OCF VS FCFCTX.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M -5M -10M -15M

1.2 Ratios

The Return On Assets of CTX (-6.09%) is comparable to the rest of the industry.
With a Return On Equity value of -8.53%, CTX perfoms like the industry average, outperforming 54.55% of the companies in the same industry.
Industry RankSector Rank
ROA -6.09%
ROE -8.53%
ROIC N/A
ROA(3y)-5.89%
ROA(5y)-4.27%
ROE(3y)-7.95%
ROE(5y)-5.81%
ROIC(3y)N/A
ROIC(5y)N/A
CTX.CA Yearly ROA, ROE, ROICCTX.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K

1.3 Margins

With a decent Gross Margin value of 51.98%, CTX is doing good in the industry, outperforming 78.79% of the companies in the same industry.
CTX's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for CTX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 51.98%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.3%
GM growth 5Y-7.9%
CTX.CA Yearly Profit, Operating, Gross MarginsCTX.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K

More info and screens

5

2. Health

2.1 Basic Checks

CTX does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, CTX has less shares outstanding
Compared to 5 years ago, CTX has less shares outstanding
Compared to 1 year ago, CTX has an improved debt to assets ratio.
CTX.CA Yearly Shares OutstandingCTX.CA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M
CTX.CA Yearly Total Debt VS Total AssetsCTX.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

2.2 Solvency

Based on the Altman-Z score of -0.93, we must say that CTX is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -0.93, CTX perfoms like the industry average, outperforming 45.45% of the companies in the same industry.
CTX has a Debt/Equity ratio of 0.01. This is a healthy value indicating a solid balance between debt and equity.
With an excellent Debt to Equity ratio value of 0.01, CTX belongs to the best of the industry, outperforming 87.88% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Altman-Z -0.93
ROIC/WACCN/A
WACC7.8%
CTX.CA Yearly LT Debt VS Equity VS FCFCTX.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M

2.3 Liquidity

CTX has a Current Ratio of 2.60. This indicates that CTX is financially healthy and has no problem in meeting its short term obligations.
CTX's Current ratio of 2.60 is fine compared to the rest of the industry. CTX outperforms 72.73% of its industry peers.
A Quick Ratio of 1.78 indicates that CTX should not have too much problems paying its short term obligations.
The Quick ratio of CTX (1.78) is better than 72.73% of its industry peers.
Industry RankSector Rank
Current Ratio 2.6
Quick Ratio 1.78
CTX.CA Yearly Current Assets VS Current LiabilitesCTX.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M

More info and screens

1

3. Growth

3.1 Past

CTX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 52.82%, which is quite impressive.
CTX shows a strong growth in Revenue. In the last year, the Revenue has grown by 20.35%.
The Revenue has been decreasing by -2.60% on average over the past years.
EPS 1Y (TTM)52.82%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%188.03%
Revenue 1Y (TTM)20.35%
Revenue growth 3Y5.3%
Revenue growth 5Y-2.6%
Sales Q2Q%52.47%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CTX.CA Yearly Revenue VS EstimatesCTX.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CTX. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CTX.CA Price Earnings VS Forward Price EarningsCTX.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CTX.CA Per share dataCTX.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 0.4 0.6 0.8 1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CTX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CRESCITA THERAPEUTICS INC

TSX:CTX (10/21/2025, 7:00:00 PM)

0.46

-0.01 (-2.13%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-06 2025-08-06
Earnings (Next)11-05 2025-11-05
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners12.78%
Ins Owner ChangeN/A
Market Cap8.67M
Revenue(TTM)20.27M
Net Income(TTM)-1332000
Analysts0
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.43
P/FCF N/A
P/OCF 6.75
P/B 0.56
P/tB 0.61
EV/EBITDA N/A
EPS(TTM)-0.07
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.01
FCFYN/A
OCF(TTM)0.07
OCFY14.81%
SpS1.08
BVpS0.83
TBVpS0.75
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -6.09%
ROE -8.53%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 51.98%
FCFM N/A
ROA(3y)-5.89%
ROA(5y)-4.27%
ROE(3y)-7.95%
ROE(5y)-5.81%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.3%
GM growth 5Y-7.9%
F-Score6
Asset Turnover0.93
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.6
Quick Ratio 1.78
Altman-Z -0.93
F-Score6
WACC7.8%
ROIC/WACCN/A
Cap/Depr(3y)37.08%
Cap/Depr(5y)28.12%
Cap/Sales(3y)2.6%
Cap/Sales(5y)2.05%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)52.82%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%188.03%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)20.35%
Revenue growth 3Y5.3%
Revenue growth 5Y-2.6%
Sales Q2Q%52.47%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y40.17%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-131.86%
FCF growth 3YN/A
FCF growth 5Y-21.27%
OCF growth 1Y185.33%
OCF growth 3YN/A
OCF growth 5Y-12.49%